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between preeclampsia cases and controls.  Discussion: We 
identified 14 potential new biomarker candidates for pre-
eclampsia and validated 4 of them by quantitative RT-PCR 
and 2 of them with subsequent serum protein analyses. Fur-
ther studies will assess the optimal marker combination for 
the imminent prediction of impending preeclampsia. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Preeclampsia is a pregnancy-specific syndrome that 
affects 2–5% of pregnancies in Western countries and 
complicates up to 10% of pregnancies in the developing 
countries, where emergency care is frequently inadequate 
or even lacking  [1] . Furthermore, it is one of the leading 
causes of maternal and fetal morbidity and mortality 
worldwide  [2, 3] . The exact pathogenesis of preeclampsia 
remains unclear, although its origin is recognized as ly-
ing in the placenta rather than the fetus itself  [3, 4] .
 At present, the only treatment for preeclampsia is de-
livery, either with induction of labor or cesarean section 
(CS). Several prophylactic therapies, such as salicylic acid, 
vitamins (C and E), calcium, antioxidants or folic acid 
supplementation, have so far showed limited benefits in 
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 Abstract 
 Introduction: Our aim was to identify novel biomarker can-
didates for the near-term prediction of preeclampsia in a ho-
mogenous collective. In this study, we screened at the ge-
nome-wide level for gene expression in placental villous tis-
sue from patients with severe preeclampsia in comparison 
to normal healthy pregnancies.  Material and Methods: To-
tal RNA was extracted from placental villous tissue from 9 
preeclamptic patients and 7 normotensive controls after 
scheduled cesarean sections. After sample pooling, gene ex-
pression analysis was performed using six Affymetrix Hu-
man Gene 1.0 ST arrays, followed by quantitative RT-PCR and 
validation of selected markers in the serum of patients at the 
protein level.  Results: In total, 896 significantly differentially 
expressed genes were identified (p  ^  0.05). After restricting 
these to molecules present in the circulation, 9 upregulated 
and 5 downregulated genes were selected. Four of them (  -
hCG, HTRA4, LHB1, all upregulated; and NOX4, downregu-
lated) were validated by quantitative real-time RT-PCR. Fi-
nally, the maternal plasma protein levels of 2 of these genes 
(LHB and   -hCG) were confirmed to be significantly different 
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high-risk groups and have failed to prove efficacious in 
the prevention of preeclampsia in apparently healthy, 
nulliparous patients  [5–7] . Therefore, widely applicable 
and affordable tests are needed to permit early diagnosis 
at presymptomatic stages in order to identify and closely 
monitor the patients at risk and thus provide the optimal 
prenatal care for these women and their fetuses.
 A number of promising candidate biomarkers for the 
early detection of preeclampsia are currently under in-
vestigation, of which biomarkers of angiogenesis are cur-
rently at the most advanced stage of development  [8] .
 A major concern is that cases of preeclampsia are mis-
diagnosed or unrecognized at admission, leading to high 
levels of maternal/fetal morbidity and mortality. There-
fore, it would be helpful to have a set of markers which 
would identify such high-risk cases of impending pre-
eclampsia  [9] .
 The use of microarrays is a powerful strategy to inves-
tigate in detail possible alterations in gene expression as-
sociated with the pathophysiology of preeclampsia at the 
genome-wide level. Although this approach has been 
used previously for the possible detection of new novel 
biomarker candidates  [10–20] , most of these studies were 
conducted in nonhomogenous collectives, which limited 
their usefulness or the conclusions that can be drawn 
from them.
 In the present study, we performed a comprehensive 
analysis of the gene expression in placental villous tissue 
samples using a homogenous collective case-control 
study. Care was taken to use matched normal controls 
and severe preeclampsia cases which were all delivered by 
CS. Quantitative RT-PCR and serum protein analyses 
were used to validate potential novel biomarker candi-
dates.
 Material and Methods 
 Study Population 
 This prospective case-control study was approved by the local 
ethical committee. After the patients had given written informed 
consent, 10 ml of EDTA blood and 10 ml of blood without antico-
agulant were taken immediately prior to delivery. All patients un-
derwent either elective CS (controls, n = 7) or scheduled CS due 
to severe preeclampsia (cases, n = 9). Severe preeclampsia was de-
fined as blood pressure  6 160/100 mm Hg, measured at least 6 h 
apart, in combination with proteinuria  6 2+ (dipstick) at least 
twice in 24 h. Patient data are summarized in  table 1 . 
 Sample Collection 
 Maternal plasma (EDTA) and serum were collected prior to 
starting the CS. Blood samples were centrifuged (2,500  g, 15 min), 
and serum was aliquoted and stored at –80  °  C until further anal-
ysis. Plasma was recentrifuged (16,000  g, 10 min) and stored in 
aliquots at –80  °  C until further analysis. Placenta specimens were 
processed in the delivery unit immediately after CS to avoid RNA 
degradation. The maternal decidua and amniotic membrane were 
removed, and pieces of villous tissue (0.5  ! 0.5  ! 0.5 cm) from 
different lobes were excised. After extensive washing (5 times) in 
sterile RNase-free cold PBS to remove remaining maternal blood, 
the sample was stored in RNAlater (Ambion, Cat. No. AM7020) 
according to the manufacturer’s instructions. Following the ad-
dition of 1.5 ml of RNAlater, the tubes were left overnight at 4  °  C 
then stored at –80  °  C.
 RNA Isolation 
 Upon removal of RNAlater, tissue was homogenized in 1 ml of 
Trizol Reagent (Invitrogen, Cat. No. 15596-026) using a Mixer 
Mill MM 301 (Retsch) in the presence of 4 stainless steel beads (1 
bead of 5 mm in diameter and 3 beads of 3 mm in diameter). Iso-
lated total RNA was further purified on RNA Clean & Concentra-
tor-5 columns (Zymo Research, Cat. No. R1016). Total RNA prep-
arations were analyzed using an Agilent 2100 Bioanalyzer. For the 
samples checked, the mean  8 SD RNA integrity number value 
was 8.6  8 0.3 (range 8.1–9.2). A NanoDrop ND-1000 Spectropho-
tometer (Thermo Scientific, USA) was used to determine RNA 
and DNA concentrations. 
 cDNA Target Synthesis and GeneChip Hybridization 
 For cDNA target synthesis, RNA samples were pooled. The 
cDNA target was synthesized, fragmented and labeled with biotin 
using the Whole Transcript Target Labeling Assay and Control 
Reagents (Affymetrix, Santa Clara, Calif., USA, Cat. No. 900652) 
starting with 270 ng of total RNA, according to the procedure de-
scribed in the GeneChip Whole Transcript Sense Target Labeling 
Assay Manual, version 4 (Affymetrix). After a first cycle of cDNA 
synthesis followed by in vitro transcription, approximately 32  8 
6   g of cRNA was obtained from each reaction. Then, 10   g of 
each sample was further used to generate single-strand cDNA, 
giving rise to approximately 6.8  8 0.4   g of cDNA. Subsequently, 
5.5   g of single-stranded cDNA was fragmented into 40–70 nu-
cleotides and monitored with the Bioanalyzer 2100 using the 
RNA Nano 6000 Chip. All synthesis reactions were carried out in 
0.5-ml tubes using a PCR machine (TProfessional, Biometra, 
Göttingen, Germany). The hybridization cocktail (80   l) con-
taining fragmented biotin-labeled target DNA at a final concen-
tration of 25 ng/  l was transferred into Affymetrix GeneChip 
Human 1.0 ST Arrays (Affymetrix, Cat. No. 901085) and incu-
bated at 45   °   C on a rotator in a hybridization oven 640 (Affyme-
trix) for 17 h at 60 rpm. The arrays were washed and stained on a 
Fluidics Station 450 (Affymetrix) using the Hybridization Wash 
and Stain Kit (Affymetrix, Cat. No. 900720) in accordance with 
the Fluidics Procedure FS450_0007. The GeneChips were pro-
cessed with an Affymetrix GeneChip  Scanner 3000 7G (Af-
fymetrix). DAT image files of the microarrays were generated 
 using an Affymetrix GeneChip Command Console (version 
0.0.0.676, Affymetrix). All experiments were performed in accor-
dance with the Minimum Information About a Microarray Ex-
periment guidelines  [21] . Data analysis was performed using 
Partek (Partek Incorporated, St. Louis, Mo., USA) for normaliza-
tion and detection of differentially expressed genes and ingenuity 
(Ingenuity Systems, Redwood City, Calif., USA) for the identifica-
tion of biomarker candidates.
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 Statistical Analysis 
 Raw gene expression data were analyzed using Partek (Partek). 
All data were log-transformed prior to analysis. 
 Normalization was carried out using quantile normalization, 
which forces all the slides to have the same intensity distribution. 
Spots on the arrays with expression values missing for  1 25% of 
the samples in the preeclampsia group or  1 25% in the control 
group were filtered out. After normalization, differential gene ex-
pression was evaluated using analysis of variance (ANOVA). A p 
value cutoff of 0.05 was applied to retrieve significantly deregu-
lated genes. To allow the identification of gene products that are 
known to be present in a specific body fluid, in our case serum 
and plasma, the list of deregulated genes was further filtered using 
the IPA biomarker tool (Ingenuity Systems). The emerging candi-
dates were then validated by quantitative real-time RT-PCR.
 For descriptive statistics, Student’s t test was used to compare 
normally distributed data between groups.  The Mann-Whitney 
U Test was used in the case of ordinal data.  Fisher’s exact test was 
used in the case of categorical data.  Statistical significance was 
assigned when a p value was less than 0.05.  All statistical analyses 
were performed using SPSS, version 12 (SPSS Inc., Chicago, Ill., 
USA).
 cDNA Synthesis and Quantitative Real-Time RT-PCR 
 cDNA was synthesized from 180 ng of total RNA according to 
the manufacturer’s instructions using the Promega Reverse Tran-
scription System (No. A3500). We were able to design oligonucle-
otides for 12 out of 14 potential biomarkers using the program 
Primer3  [22] , which were then synthesized by Microsynth AG, 
Switzerland. PCR reactions were performed in a total volume of 
25   l on an ABI Prism 7000 detection system (Applied Biosys-
tems) using the default cycling conditions. For each reaction, 1   l 
of cDNA template, 12.5   l of 2 ! ABI SYBR green master mix (No. 
4367659) and 300 n M of each sense and antisense primer were 
used.
 Serum Analyses 
 Serum concentrations of   -human chorionic gonadotropin 
(  -hCG) were analyzed on a Cobas  e601 using the appropriate 
kit (No. 03271749-190). Luteinizing hormone   polypeptide 
(LHB) was quantified using an LHB ELISA from Genway Biotech 
(No. 40-056-205015) according to the manufacturer’s instruc-
tions.
 Results 
 We compared gene expression profiles of approxi-
mately 28,000 genes using 9 villous tissue samples from 
women with severe preeclampsia and 7 normotensive 
controls, pooled into 4 and 2 Affymetrix Human 1.0 ST 
arrays, respectively. 
 After normalization, ANOVA comparative analysis 
between pooled controls and pooled preeclampsia cases 
resulted in 896 significantly differentially expressed 
genes (p  ^  0.05), belonging to various pathways includ-
ing riboflavin metabolism, leukocyte extravasation sig-
naling, NF-  B signaling and chemokine signaling. 
 To achieve the goal to detect potential biomarkers, we 
filtered these 896 genes with the IPA biomarker tool to 
Table 1.  Maternal and fetal characteristics
Characteristic Controls (n = 7) Preeclamptic patients 
(n = 9)
p value
Maternal age, years 35.1 (33/37) 36.8 (22/43) NS
Gestational age, weeks 38.6 (38/41) 34.6 (33/39) NS
Prepregnancy body mass index 21.1 (18.5/37.1) 26.3 (20.0/33.9)a 0.072
Body mass index at delivery 26.4 (22.1/41.3) 32.4 (22.8/36.3) NS
Gain in body mass index 4.5 (3.6/7.2) 4.8 (2.4/9.9)a NS
Systolic blood pressure, mm Hg 123 (105/144) 179 (150/220) 0.001
Diastolic blood pressure, mm Hg 71.0 (65/83) 105 (90/140) 0.001
Proteinuria (dipstick) negative +++ 0.000
Multipara 0/7 2/9 NS
Nullipara 2/7 7/9 0.072
Fetal sex: male/female 3/7 3/11 NS
Infant birth weight, g 3,140 (2,970/4,300) 1,810 (1,300/3,420)b 0.002
IUGR (<3rd percentile) 0/7 4/11b NS
Preterm delivery (<37 weeks of gestation) 0/7 7/9 0.003
V alues are expressed as medians (minimum/maximum), where applicable. IUGR = Intrauterine growth re-
striction; NS = not significant. a Data for 8 of 9 patients with preeclampsia. b Data for 11 children born from 9 
patients with preeclampsia.
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Table 2.  Selected potential biomarkers for the detection of preeclampsia
Assignment/abbreviation/name/location Fold
change
(array)
Significant
fold change
(qRT-PCR)
Function
1 NM_000737/CGB/chorionic gonadotropin,
 polypeptide/19q13.32
4.34 d 8 d glycoprotein hormone, maintenance of pregnancy 
2 NM_153692/HTRA4/HtrA serine peptidase 
4/8p11.23
4.03 d 8.3 d degradation of misfolded secretory proteins
3 NM_001882/CRHBP/corticotropin-releasing 
hormone-binding protein/5q11.2
2.01 d NA corticotropin-releasing hormone-binding protein 
inactivates corticotropin-releasing hormone, which may 
prevent inappropriate pituitary-adrenal stimulation in 
pregnancy
4 NM_000894/LHB/luteinizing hormone  
polypeptide/19q13.32
1.71 d 13 d promotion of spermatogenesis and ovulation
5 NM_012413/QPCT/glutaminyl-peptide 
cyclotransferase (glutaminyl cyclase)/2p22.2
1.63 d NS transfers pyroglutamyl residues to activate different 
neuroendocrine peptides
6 NM_078481/CD97/CD97 molecule/19p13 1.61 d NS 7-span transmembrane protein involved in cell adhesion 
and signaling processes early after leukocyte activation
7 NM_002429/MMP19/matrix metallopeptidase 
19/12q14
1.61 d NS breakdown of extracellular matrix, embryonic 
development, reproduction, tissue remodeling
8 NM_001464/ADAM2/ADAM 
metallopeptidase domain 2 (fertilin )/8p11.2
1.39 d NS membrane-anchored protein involved in cell-cell 
and cell-matrix interactions, fertilization, muscle 
development and neurogenesis as well as a subunit of an 
integral sperm membrane glycoprotein called fertilin, 
which plays an important role in sperm-egg interactions
9 NM_005538/INHBC/inhibin,  C/12q13.1 1.26 d NS belongs to the transforming growth factor- hormone 
superfamily and is involved in hormone secretion and 
growth and differentiation in various cell types
10 NM_002983/CCL3/chemokine (C-C motif) 
ligand 3/17q11–q21
1.16 f NA involved in the acute inflammatory state in the 
recruitment and activation of polymorphonuclear 
leukocytes
11 NM_016931/NOX4/nicotinamide adenosine 
dinucleotide phosphate oxidase 4/11q14.2–q21
1.69 f 6.5 f acts as oxygen sensor
12 NM_001078/VCAM1/vascular cell adhesion 
molecule 1/1p32–p31
1.78 f NS mediates leukocyte-endothelial cell adhesion and signal 
transduction
13 NM_006732/FOSB/FBJ murine osteosarcoma 
viral oncogene homolog B/19q13.3
1.92 f NS leucine zipper protein, involved in the formation of 
activator protein-1 transcription complexes to induce 
proliferation, differentiation and transformation
14 NM_001337/CX3CR1/chemokine (C-X3-C 
motif) receptor 1/3p213p21.3
1.96 f NS involved in T cell homing and recruitment of immune 
cell populations
Q uantitative RT-PCR (qRT-PCR) validations of 14 biomarker candidates. Threshold cycle values were normalized to GAPDH. Sta-
tistical significances were calculated using ANOVA. NA = Not applicable; NS = not significant.
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further select for those candidates which could poten-
tially be present in the circulation (serum or plasma). By 
this selection process, we obtained 14 potential biomark-
er candidates, of which 9 were upregulated and 5 were 
downregulated, as follows:   -hCG (4.34 !  d ), HTRA4 
(4.03 !  d ), CRHBP (2.01 !  d ), LHB (1.71 !  d ), QPCT 
(1.63 !  d ), CD97 (1.61 !  d ), MMP19 (1.61 !  d ), ADAM2 
(1.39 !  d ), INHBC (1.26 !  d ), CCL3 (1.16 !  f ), NOX4 
(1.69 !  f ), VCAM1 (1.78 !  f ), FOSB (1.92 !  f ) and
CX3CR1 (1.96 !  f ). The results of this screen are summa-
rized in  table 2 . 
 To validate these microarray results, real-time quanti-
tative RT-PCR was performed, in which the expression 
levels of 12 of the 14 candidate genes ( table 2 ) could be suc-
cessfully quantified. Two of the 14 (CCL3 and CRHBP) 
could not be evaluated. For these analyses, cDNA was syn-
thesized from the same RNA preparations that were used 
for microarray examinations. Results were normalized 
using the housekeeping gene GAPDH (encoding glycer-
aldehyde 3-phosphate dehydrogenase), and fold changes 
were calculated using the    threshold cycle method 
 [23] . The results of those validations are shown in  table 2 
as ratios of the threshold cycle values of the gene of inter-
est and the threshold cycle value of GAPDH, respectively. 
 Among the 12 tested genes, we observed a significant 
concordance (p  ^  0.05) with the results obtained by mi-
croarray analysis for 4 genes, namely   -hCG (upregulat-
ed), HTRA4 (upregulated), LHB (upregulated) and NOX4 
(downregulated). 
 To investigate the eligibility of the validated candi-
dates as biomarkers which could be present in the mater-
nal circulation, two proteins, namely   -hCG and LHB, 
were subsequently examined in the maternal serum sam-
ples that were collected at the time of delivery.  Figure 1 
shows a box plot of the maternal serum   -hCG and LHB 
levels. The mean  8 SD concentration of   -hCG in serum 
samples from women with preeclampsia was significant-
ly higher than in the controls (68,900  8 51,980 vs. 18,100 
 8 15,330 IU/l; p = 0.03). The median concentration of 
LHB in preeclamptic serum samples was significantly 
higher than in the controls (0.739  8 0.107 vs. 0.631  8 
0.022 IU/l; p = 0.05).
 Discussion 
 The present study represents a comprehensive analysis 
of a microarray RNA expression profile of placental vil-
lous tissue processed immediately after scheduled CS 
from patients with severe preeclampsia and healthy con-
trols, with the use of RNA microarray technology and 
further validation with quantitative real-time RT-PCR 
and serum protein level determination. Nine upregulated 
and 5 downregulated genes were selected from 896 sig-
nificantly differentially expressed genes, on the basis of 
possible presence in maternal serum, a vital requisite for 
putative biomarkers. In 12 out of these 14 instances, 
quantitative real-time RT-PCR was successfully per-
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 Fig. 1. Maternal serum levels of β-hCG (a) and LHB (b) 2 h before CS. a p = 0.03 (asymp. sig. 2-tailed, Mann-
Whitney U test). b p = 0.05 (asymp. sig. 2-tailed, Mann-Whitney U test).
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formed to confirm expression levels determined by mi-
croarray analysis, showing significant differences in 4 
potential markers (  -hCG, HTRA4 and LHB, all upregu-
lated; NOX4, downregulated). Furthermore, to verify the 
detectability of the gene products in maternal blood, we 
measured the protein concentration of 2 of these 4 candi-
dates in serum samples that were collected together with 
the tissue samples prior to CS. 
 Similar to other studies using a microarray RNA ex-
pression profile of placental villous tissue of preeclamptic 
patients, we found differentially expressed genes such as 
  -hCG  [24] or LHB, which could be the result of altered 
trophoblast physiology  [25] . The elevated levels of these 
molecules, which are predominantly expressed in the 
syncytiotrophoblast, may be indicative of altered path-
ways that are related to uteroplacental vascular insuffi-
ciency or placental oxidative stress and reoxygenation 
 [26] .
 Amongst the genes whose expression was significant-
ly upregulated was HTRA4, a serine peptidase responsi-
ble for the hydrolysis of misfolded proteins. The mRNA 
level of this gene was elevated approximately 4-fold in 
placentae from women with preeclampsia when com-
pared to normal controls. This is in accordance with a 
recently published study which exhibited similar results 
for HTRA1, a member of the family of HTRA proteins, 
which is a secreted multidomain protein with serine pro-
tease activity and which is involved in the physiological 
development of many organs as well as in the develop-
ment of several pathologies  [27, 28] .
 Amongst the genes whose expression was downregu-
lated, it was interesting that we observed a significant de-
crease in the expression of NOX4, as this gene product is 
involved in blood pressure regulation and endothelial cell 
survival, vital features in the pathophysiology of pre-
eclampsia  [29] . This decrease in expression may be ex-
plained by preexisting high levels of superoxide in the 
preeclamptic placenta  [30] , due to increased production 
of superoxide within the placenta by abnormal mito-
chondria, increased activity of xanthine oxidase  [31] and 
endothelial nitric oxide synthase  [32] .
 Amongst the candidate biomarkers for which we could 
determine mRNA as well as protein expression levels was 
  -hCG. For this protein, we detected increased concen-
trations in the maternal circulation in patients with pre-
eclampsia in comparison to controls. This could serve to 
indicate that the increased   -hCG concentrations may be 
an effect of the disease and not caused by gestational age 
differences of the subjects in our study. Similarly, serum 
levels of LHB were significantly elevated in the maternal 
circulation, which may be the result of altered trophoblast 
physiology.
 The strength of this study was the homogenous case-
control collective, in which care was taken to match pa-
tients with diagnosed severe preeclampsia and healthy 
normal controls. A further important feature was that 
the deliveries in both groups were performed by CS, 
thereby eliminating an important confounder between 
the study and control groups  [33] . This permitted us to 
determine an altered gene expression profile in cases of 
preeclampsia when compared to matched healthy con-
trols. By this means, we were able to detect 14 genes en-
coding putative secreted biomarkers present in maternal 
serum. 
 Our use of placentae immediately after delivery may 
assist with the development of biomarkers to detect preg-
nancies at risk for imminent preeclampsia. This is a major 
clinical concern, as many such cases are inadequately 
identified at admission  [9] .
 Further studies are ongoing to investigate whether the 
expression of these genes is altered during gestation in 
those cases that subsequently develop preeclampsia and 
thereby to determine the predictive value of these candi-
date biomarker molecules.
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